NASDAQ:COGT - Cogent Biosciences Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $17.50
Forecasted Upside: 93.16 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$9.06 As of 06/15/2021 01:00 AM ET

▼ -0.05 (-0.55%)

1 month | 3 months | 12 months

Get New Cogent Biosciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for COGT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COGT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$17.50

▲ +93.16% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $17.50, with a high forecast of $24.00 and a low forecast of $4.00. The average price target represents a 93.16% upside from the last price of $9.06.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Cogent Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/4/2021	Lifesci Capital	Reiterated Rating	Outperform		N/A	i Rating by S. Slutsky at Lifesci Capital
12/23/2020	Piper Sandler	Initiated Coverage	Overweight	$22.00 ➝ $22.00	N/A	i
12/16/2020	SVB Leerink	Initiated Coverage	Outperform	$20.00	N/A	i Rating by C. Liu at SVB Leerink LLC
11/10/2020	Wedbush	Boost Price Target	Outperform	$6.00 ➝ $24.00	N/A	i
10/14/2020	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$4.00	N/A	i
4/12/2018	Barrington Research	Initiated Coverage	Outperform ➝ Outperform	$4.00	Low	i
2/27/2018	Chardan Capital	Set Price Target	Buy	$7.00	High	i Rating by James McIlree at Chardan Capital
2/26/2018	Barrington Research	Reiterated Rating	Buy	$4.00	Medium	i
11/9/2017	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$12.50 ➝ $7.00	N/A	i
8/8/2017	Roth Capital	Set Price Target	Buy	$8.00	Medium	i Rating by William Gibson at Roth Capital
6/29/2017	Roth Capital	Initiated Coverage	Buy	$7.65	Medium	i Rating by W. Gibson at Roth Capital
3/13/2017	Chardan Capital	Reiterated Rating	Buy	$12.50	Medium	i
11/4/2016	Chardan Capital	Reiterated Rating	Buy	$12.50	N/A	i
10/21/2016	Chardan Capital	Reiterated Rating	Buy	$12.50	N/A	i
10/14/2016	Barrington Research	Reiterated Rating	Outperform	$7.00	N/A	i
7/12/2016	Barrington Research	Reiterated Rating	Outperform		N/A	i Rating by J. Goss at Barrington Research

(Data available from 6/16/2016 forward)

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $9.06

$8.79

$9.59

50 Day Range

MA: $8.38

$7.82

$9.11

52 Week Range

Now: $9.06

$1.61

$14.88

Volume

806,934 shs

Average Volume

338,896 shs

Market Capitalization

$347.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Cogent Biosciences?

The following sell-side analysts have issued research reports on Cogent Biosciences in the last twelve months: LADENBURG THALM/SH SH, Lifesci Capital, Piper Sandler, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for COGT.

What is the current price target for Cogent Biosciences?

4 Wall Street analysts have set twelve-month price targets for Cogent Biosciences in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 93.2%. Wedbush has the highest price target set, predicting COGT will reach $24.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $4.00 for Cogent Biosciences in the next year.
View the latest price targets for COGT.

What is the current consensus analyst rating for Cogent Biosciences?

Cogent Biosciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COGT will outperform the market and that investors should add to their positions of Cogent Biosciences.
View the latest ratings for COGT.

What other companies compete with Cogent Biosciences?

Other companies that are similar to Cogent Biosciences include Precigen, Zealand Pharma A/S, DiaMedica Therapeutics, Stoke Therapeutics, Nurix Therapeutics, Northwest Biotherapeutics, ImmunoGen, Innoviva, Endo International, Vectura Group, Edgewise Therapeutics, MacroGenics, Olema Pharmaceuticals, Keros Therapeutics and Phibro Animal Health.

How do I contact Cogent Biosciences' investor relations team?

Cogent Biosciences' physical mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company's listed phone number is 561-757-4000 and its investor relations email address is [email protected] The official website for Cogent Biosciences is www.cogint.com.